HUM's Star Ratings recovery is set to show early progress, but October's CMS release will test its MA turnaround and path to a 2028 margin target.

UNH's improving medical costs, higher EPS estimates and capital returns support its recovery, but regulatory risks remain.

CVS delivers strong Q2 growth and raises 2026 targets, but Caremark pressures and medical costs are likely to shape its next move.

Elevance Health (ELV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Pushed to their limits, patients are turning to social media to plead for help getting their medical care covered.

Elevance Health has delivered a 37.6% gain over the past year, yet current valuation checks still lean on the side of the stock looking inexpensive rather than stretched. For investors, that creates a pricing debate around how much of the company’s recent health data partnerships and care model initiatives is already reflected in today’s US$398.22 share price. Over the last 12 months Elevance Health is up 37.6%. This puts recent shareholders in a comfortable spot and raises the bar for what...

Management had named the plan exits, the Medicare margin target and the repricing date before the run began.

Management has raised its full-year earnings outlook twice, and the segment doing most of the lifting is still short of its own target margin.

HUM's HealthStream deal backs 1,000 caregiver scholarships and new tools to improve recruitment and retention in Indiana.

UnitedHealth's lower medical costs are fueling an earnings recovery, but rising commercial costs and 2027 pricing decisions could test its durability.

In the health insurance arena, one company is both the undisputed leader and the most expensive ticket, forcing investors to decide if paying up for quality is a winning strategy.

EHC beats Q2 earnings estimates as higher patient revenues and strong discharge growth drive results, leading the company to raise its 2026 adjusted EPS outlook.